Vaccine Allocation in a Declining Epidemic by Wallinga, J. et al.
 
Vaccine Allocation in a Declining Epidemic
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Goldstein, E., J. Wallinga, and M. Lipsitch. 2012. Vaccine
allocation in a declining epidemic. Journal of the Royal Society
Interface 9(76): 2798-2803.
Published Version doi:10.1098/rsif.2012.0404
Accessed February 19, 2015 11:50:00 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10579678
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAVaccine allocation in a declining
epidemic
E. Goldstein1,*, J. Wallinga3 and M. Lipsitch1,2
1Center for Communicable Disease Dynamics, Department of Epidemiology, and
2Department of Immunology and Infectious Diseases, Harvard School of Public Health,
Boston, MA 02115, USA
3Centre for Infectious Disease Control, National Institute of Public Health and the
Environment (RIVM), 3720 BA Bilthoven, The Netherlands
Sizeable quantities of 2009 pandemic inﬂuenza A/H1N1 (H1N1pdm) vaccine in the USA
became available at the end of 2009 when the autumn wave of the epidemic was declining.
At that point, risk factors for H1N1-related mortality for some of the high-risk groups,
particularly adults with underlying health conditions, could be estimated. Although those
high-risk groups are natural candidates for being in the top priority tier for vaccine allocation,
another candidate group is school-aged children through their role as vectors for transmission
affecting the whole community. In this paper, we investigate the question of prioritization for
vaccine allocation in a declining epidemic between two groups—a group with a high risk of
mortality versus a ‘core’ group with a relatively low risk of mortality but fuelling transmission
in the community. We show that epidemic data can be used, under certain assumptions on
future decline, seasonality and vaccine efﬁcacy in different population groups, to give a cri-
terion when initial prioritization of a population group with a sufﬁciently high risk of
epidemic-associated mortality is advisable over the policy of prioritizing the core group.
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1. INTRODUCTION
Approximately 62–65% of fatalities among hospitalized
H1N1pdm patients were in adults with underlying
health conditions other than pregnancy [1,2]. These
statistics were obtained during the early stages of an
epidemic, when most children were still susceptible to
infection; as the epidemic progressed, the proportion
of infections among adults (and thus among high-risk
adults) would probably increase [3].
Suchestimatesofthefractionofdeathsassociatedwith
particular high-risk conditions, combined with estimates
of the prevalence of such conditions [1,4–7], permit esti-
mation of the relative risks for mortality among persons
with these conditions. Among the groups at the highest
risk of dying of pandemic inﬂuenza in 2009 were those
with renal disease, neurological disorders and perhaps
immunosuppression. Providing vaccine to individuals in
such groups has a large immediate beneﬁt in preventing
mortality, assuming that the vaccine is effective in
such groups. On the other hand, vaccination of healthy
school-aged children, who are not at high risk of dying,
hasabeneﬁtintermsofreducingtransmissioninthecom-
munity and decreasing the rate of transmission, which
would in turn beneﬁt the whole community, including
high-risk adults, who form the majority of fatalities.
This beneﬁt is particularly pronounced during the early
stages of an epidemic; later on its effect is dampened
because fewer children are susceptible, hence children
play a lesser role in transmission [8]. Prior studies [9,10]
have suggested that vaccination of children is optimal, in
various senses, when vaccine is available in substantial
quantities relatively early in an epidemic, while vacci-
nation of higher risk groups may be more beneﬁcial if
vaccine supplies are limited and become available late
in an epidemic. These considerations lead to a natural
quantitative question: Under what conditions is direct
vaccination of the high-risk group members superior as a
strategytovaccinationofchildrentoreducetransmission?
The question we consider here is as follows: suppose
that small, initial quantities of a vaccine are becoming
available during a declining epidemic. Should we give
them to the population stratum whose relative risk of
fatality is high, or should we give them to the stratum
whose relative risk of fatality is low (below average), but
w h i c hh a sas t r o n gi m p a c to n the epidemic’s dynamics
in the whole population? The measure of the beneﬁt in
both scenarios is the total number of lives that are to
be saved throughout the remainder of the epidemic.
We propose to answer this question using a more
ﬂexible approach than that adopted in prior studies
[9,10]. First, we do not assume knowledge of contact
and transmission patterns in different population
groups; rather, prioritization is guided by the available
data on the epidemic’s decline rate. Second, we do not
assume that high-risk adults play the same role in the
transmission process as adults without underlying
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fewer contacts, particularly with children, and may
play a very limited role in transmission to others;
in this context, the beneﬁt of allocating vaccine to
high-risk adults is only measured using data on their
share among the severe outcomes. Third, the approach
in both studies [9,10] assumes that a certain vaccine
quantity is delivered at once (with no further vac-
cine distribution) and compares the effect of that
allocation for high transmission versus high-risk individ-
uals. In practice, vaccine is produced and distributed
gradually during an epidemic. We make no assumption
on future vaccine availability in formulating the priori-
tization criterion. We assume only that the overall
transmissibility of the virus does not increase after the
point at which the vaccine allocation decision is made; if
changing weather or other seasonal factors increase trans-
mission opportunities [11], we assume that such increases
are offset by decreasing numbers of susceptible hosts.
Here, we consider this question speciﬁcally in the con-
text of a declining epidemic. We note that for the 2009
H1N1 inﬂuenza epidemic in the USA, sizeable vaccine
quantities became available during the epidemic’s declin-
ing stage, and, according to recommendations made by
the Advisory Committee on Immunization Practices
(ACIP) [12], healthy children aged 5–18 and adults
with underlying health conditions had the same priority
for vaccination. Surveillance data such as those collected
by the US Centers for Disease Control and Prevention
(CDC) [13] can be used to estimate the weekly decline
rate of epidemic incidence. Using this rate and several
assumptions, we formulate conditions under which initial
prioritization of the high-risk group over the core group is
advantageous. We calibrate those conditions against the
available data in the USA and assess their relevance for
the 2009 H1N1 pandemic, emphasizing several sources
of uncertainty, particularly with regard to vaccine
efﬁcacy (VE) against fatal outcomes for high-risk adults.
2. METHOD AND RESULTS
2.1. Relative risk between population groups
Let X and Y be two population subgroups—for example,
morbidly obese persons and persons with cancer (note:
some individuals may be members of both groups). We
deﬁne the relative risk Rt(X,Y) for mortality in group
X compared with group Y at time t to be the ratio of
the risk of mortality in group X at time t and the corre-
sponding risk in group Y. Here, the risk of mortality in a
particular group at time t is the number of deaths in that
group at time t divided by the size of that group.
Data on the prevalence of various underlying con-
ditions among the fatal cases collected during the
early stages of an epidemic (e.g. [1,2]), combined with
prevalence data for different underlying medical con-
ditions in the population allow for an assessment of
Rearly(X,W)—the relative risk of mortality in the var-
ious high-risk groups X compared with the whole
population W during the early stages of the epidemic.
We assume that, even as the epidemic progresses,
the relative risk for any unvaccinated subgroup of the
high-risk group X is at least
RR ¼ RearlyðX;WÞ: ð2:1Þ
That is, the relative risk of the high-risk group does not
decline during the epidemic, relative to the whole popu-
lation. Although we are not aware of data conﬁrming
that assumption, depletion of susceptibles among children
and young adults suggests that their relative share among
the infected decreases (which could be seen in the decrease
of their share among the inﬂuenza-like illness (ILI) cases
during the H1N1 pandemic [14]), and the share of other
population groups (and correspondingly their relative risk
of fatality) should increase. The latter increase might not
beuniforminallpopulationgroups—seemoreonthatin§3.
Table 1 summarizes the prevalence of adults with cer-
tain underlying conditions among the fatal H1N1pdm
cases in Fowlkes et al. [1] and Louie et al. [2], and their
estimated relative risk of fatality.
2.2. Effect of vaccination
2.2.1. Targeted vaccination strategies for a limited
quantity of vaccines
Suppose that we have enough vaccine to give one dose
to a proportion q of the whole population—thus, q is
the number of vaccine doses divided by the number of
persons in the whole population W. We wish to com-
pare various vaccination strategies for this limited
Table 1. Prevalence among fatal cases from Fowlkes et al. [1] and Louie et al. [2] and relative risk (RR) for H1N1pdm fatality
for certain underlying health conditions in US adults. Ranges are the exact (Clopper and Pearson) conﬁdence intervals for
each study. For prevalence of morbid obesity among the fatalities in Fowlkes et al. [1], limited body mass index (BMI) data are
available, and no absolute counts are reported.
underlying condition (adults) share among US fatalities
share among US
population (%) RR for fatality
renal disease 12.3% (9–16.4%) [1] 1.288 9.6 (7–12.8) [1]
15.3% (9.3–23%) [2] 11.9 (7.2–17.9) [2]
neurological disorder/developmental delay 9.9% (6.9–13.7%) [1] 0.91 10.9 (7.5–15) [1]
11.9% (6.6–19.1%) [2] 13.0 (7.3–21) [2]
immunosuppressive condition 17.6% (13.6–22.2%) [1] 1.9 9.2 (7.2–11.7) [1]
morbid obesity (BMI  40) 8.9% [1] 4.47 2.0 [1]
31.5% (21.2–43.2%) [2] 7.1 (4.8–9.7) [2]
chronic obstructive pulmonary disease 13% (9.5–17.1%) [1] 3.33 3.9 (2.9–5.1) [1]
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the number of subsequent deaths is lowest.
UnderstrategyHR,thisvaccinequantityisgiventothe
high-riskgroup X.Under strategy C, thisvaccine quantity
is given to the core group (children). The only difference
between strategy HR and strategy C is in the distribution
of this quantity q; we assume that the subsequent
distribution of vaccine doses beyond q i st h es a m ei n
both strategies. A reference strategy, referred to as N,
leaves this vaccine quantity q unused, the subsequent
distribution being identical to the HR and C scenarios.
We denote the vaccine efﬁcacy against infection in
some population group G by VEI
G, and vaccine efﬁcacy
against death by VED
G. We are mostly interested in esti-
mating the ratio of the vaccine efﬁcacy against death
VED
HR for the high-risk group and the vaccine efﬁcacy
against infection VEI
G for children:
ER ¼
VED
HR
VEI
C
: ð2:2Þ
Although we are not aware of data allowing for the
estimate of the efﬁcacy ratio (ER), we note that vaccine
efﬁcacy against death in any given group might be
higher than the efﬁcacy against infection, based on
the idea that a limited antibody response to vacci-
nation, insufﬁcient to prevent infection, might still
mitigate illness to prevent a fatal outcome.
2.2.2. Acomparisonresultbetweenvaccinationstrategies
To formulate our main result, we introduce some nota-
tion. Let w() be the serial interval distribution for
inﬂuenza (which we assume to be no longer than 7
days), and let m be its mean.
Let t0 be the day when vaccine quantity q takes
effect, and r0 be the epidemic’s daily exponential decline
rate at that time.
Suppose that distributing quantity q to the core
group decreases the effective reproductive number of
the epidemic by a fraction Aq.
Finally, we assume that for the week beyond t0 the
decline rate does not change much under scenario N.
Underthisassumption,wedemonstrate(seetheelectronic
supplementary material) that an initial campaign
prioritizing the high-risk group over the core group is
advantageousintermsofreducingcumulativemortalityif
VED
HR   RR   A
1
emr0   1
þ
1
1   e 7r0

: ð2:3Þ
2.2.3. Assessing the prioritization criterion for the 2009
H1N1pdm data in New England
There is some variability in estimates of the serial inter-
val distribution in the literature [15–18]. One can
estimate from those papers that the mean m of the
serial interval distribution is at least 2.5 days.
To estimate the epidemic’s decline rate r at different
time points, we use surveillance data such as those col-
lected by the CDC [13] following the approach in
Goldstein et al. [19]. The weekly incidence of inﬂuenza
IWtw for week tw is estimated to be the proportion of
ILI among doctor visits multiplied by the proportion
of collected specimens testing positive for inﬂuenza
during that week. The incidence estimate is given up to
(an unknown) multiplicative factor; however, the ratio
IWtw
IWtw 1
, 1
can be thought of as the estimate of the decline rate in
incidence during week tw.
Let the daily exponential rate of change in incidence
during the week tw (assumed constant over that week)
be rw. It is estimated from
e 7rw ¼
IWtw
IWtw 1
:
Estimates of the decline rates of the epidemic at the
time when sizeable quantities of the vaccine appeared in
2009 varied signiﬁcantly by different regions in the USA.
New England had robust decline rates of the epidemic by
the end of November/early December 2009, with the
decline subsequently sustained in the winter. Table 2
gives estimates of the daily decline rate between weeks 45
and 48 in New England, on the basis ofthe ILIand the res-
piratoryspecimen testing data collected by the CDC [14].
A method to estimate A in equation (2.3) from the
epidemic data appears in Wallinga et al. [8]. This
method suggests that
A ¼ VEI
C   Ap;
where Apq would be the reduction of the reproductive
number under the distribution of quantity q of a perfect
vaccine to children. Equation (2.3) suggests that a cri-
terion for prioritization of a high-risk group with the
epidemic’s daily decline rate being r is
RR  
Ap
ER
1
e2:5r   1
þ
1
1   e 7r

: ð2:4Þ
We note that since 0–17 year olds constituted 24.3
per cent of the US population in 2009 [20], and since
giving perfect vaccine at random to a fraction q of the
population reduces the reproductive number by a frac-
tion q, one necessarily has that Ap   1/0.243 ¼ 4.12
(the latter would be true if other population groups
had no impact on the epidemic). Estimation of Ap
based on the method in Wallinga et al. [8] applied to
the data from the 2009 H1N1 inﬂuenza epidemic in
the USA is described in the electronic supplementary
material. This method suggests a bound
Ap   2:15: ð2:5Þ
Figure 1 plots a range of values for the decline rate r
and the relative risk of a fatal outcome, for which our
criterion suggests the prioritization of the high-risk
group over children for Ap¼ 2.15 and 2.5, assuming
Table 2. Daily exponential decline rate between weeks 45
and 48 in New England.
week 45–46 46–47 47–48
daily decline rate r 0.093 0.099 0.12
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region, plotted in grey, our criterion is inconclusive,
and no prioritization recommendation either for
children or for the high-risk adults can be made.
Finally, applying the criterion in equation (2.4) with
Ap  2.15 (as estimated from the epidemic data in
the electronicsupplementary material) under the assump-
tion that ER 1 suggests that, by week 48 of 2009 in New
England, prioritization of adults with neuromuscular
disorders, renal disease and possibly immunosuppression
over healthy children was advisable. On the other hand,
if ER is signiﬁcantly lower than 1, it might have been the
case that prioritizing school-aged children was advisable
owing to the effect of vaccinating children on the epidemic
dynamics andmortality inthewhole community.We note
that, in New England, adherence to the ACIP guidelines
[12] giving equal priority to healthy school-aged children
and adults with underlying healthconditions was adopted
by the local health departments [21,22].
2.2.4. Practical considerations behind prioritization of
high-risk individuals
Our proposed strategy is that, when a small quantity of
vaccine becomes available during the declining phase of
an epidemic, prioritizing high-risk adults can reduce
overall mortality compared with prioritizing healthy
children, provided the adults in the priority group are
at high enough risk, as deﬁned in equation (2.3).
When sizeable proportions of the population are already
vaccinated, or when the criterion in equation (2.3) is
not met, prioritizing high-risk adults might not be war-
ranted, and a larger impact can potentially be obtained
by prioritizing children rather than high-risk adults to
accelerate the epidemic’s decline.
Wealsonotethatourapproachassumesthefeasibility
of implementing a ﬂexible vaccine distribution policy.
Such a policy would entail a switch from an initial,
short-term drive to vaccinate certain groups of high-risk
individuals to a campaign for vaccinating children.
Prior planning of resources to reach those high-risk indi-
viduals, which includes fostering their awareness about
the risks they are facing, and the ability to redirect the
targeting of the available vaccine on a timely basis are
necessary for the approach to be successful.
3. DISCUSSION
This paper examines prioritization for vaccine allo-
cation in a declining inﬂuenza epidemic. It formulates
conditions under which an initial campaign to vaccinate
individuals with a high risk of mortality from inﬂuenza
is preferable to vaccinating a core group, like children,
which has a relatively low risk of mortality but fuels
transmission in the community. It is shown how those
conditions can be validated in real time under a range
of uncertainties in the estimates of certain quantities
related to the epidemic’s progression and VE. We
note that, for an emerging epidemic, priority for vaccine
allocation with the goal of minimizing the overall mor-
tality burden may go to school-aged children rather
than adults with underlying health conditions [9,10].
Abasicsourceofuncertaintyinapplyingtheprioritiza-
tion criterion isthe need foran estimateof vaccine efﬁcacy
against fatal outcomes in various high-risk groups.
Althoughwearenotawareofdataassessingtheaboveefﬁ-
cacy, several studies estimating the immunogenicity and
efﬁcacy against infection in different high-risk groups for
the vaccine against the 2009 A/H1N1 inﬂuenza have
been published. A case–control study has found poor
immuneresponsetovaccination in haemodialysispatients
[23].Someobservationaldataarenowavailableonvaccine
efﬁcacy against infection among the high-risk groups for
the 2009 H1N1 inﬂuenza pandemic [24–26]. These data
suggest that vaccine efﬁcacy against infection is lower in
high-risk individuals than in healthy children. However,
observational studies of inﬂuenza vaccine effectiveness
may be subject to signiﬁcant residual confounding,
especiallyamong high-risk persons [27]. Moreover, vaccine
efﬁcacy against fatal outcomes among high-risk adults
might be different, either afﬁrming the rationale behind
their prioritization as indicated by our approach or
suggesting that low efﬁcacy in direct protection of high-
risk adults makes prioritization of school-aged children
advisable because of the effect of vaccinating children on
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Figure 1. Ranges for the epidemic decline rate r and the relative risk (RR) for mortality in a high-risk group (red) for which prior-
itization of the high-risk group is justiﬁable under equation (2.4) for different values of the parameter Ap, under the assumption
that ER   1. (a) Ap ¼ 2.15 and (b) Ap ¼ 2.5.
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munity. Another source of uncertainty related to the
impact of vaccination is the potential detrimental short-
term effect that vaccination might have on susceptibility.
Data from Emborg et al. [25] suggest a negative and
statistically signiﬁcant vaccine efﬁcacy against infection
occurring within a week from vaccination. Given that, in
adecliningepidemic,asizeablefractionoffutureinfections
are likely to occur within a fairly short time, such an effect
may take away from the beneﬁt of vaccinating high-risk
individuals, although it may also have an impact on
vaccinating children.
Another potential source of uncertainty in priori-
tizing high-risk adults is the feasibility of a timely
implementation of a vaccination campaign for those
groups. For children, rapid administration of a vaccine
is possible through school-based vaccination drives.
High-risk adults might be a harder target group to
reach, with past efforts concentrated on their healthcare
providers [28,29]. A combination of risk awareness and a
speedy distribution framework is needed to ensure that
vaccine allocation to high-risk adults would not lag sig-
niﬁcantly behind an alternative of administering the
corresponding vaccine quantity to children.
Besides vaccine efﬁcacies in different population
groups, the key quantities needed to ascertain our prior-
itization criterion are the epidemic’s decline rate and the
impact of vaccinating the core group (children) on the
epidemic’s reproductive number. The decline rate can
be estimated from surveillance data, such as those col-
lected by the CDC [13], using a proxy for inﬂuenza
incidence described in Goldstein et al. [19]. The impact
of vaccinating the core group on the reproductive
number can be gauged following the method in Wallinga
et al. [8]. That method requires knowledge of the relative
susceptibility and infectivity in different population
groups, and the epidemic’s incidence curve stratiﬁed by
those groups. Data on relative susceptibility and infectiv-
ity in different age groups can be obtained from
household studies and may, in principle, become available
in real time; we have borrowed the estimates from
Cauchemez et al. [16], which was published at the end
of2009.Wedidnothaveagoodestimateoftheepidemic’s
incidence curve; instead, we have adapted the method in
Wallinga et al. [8] to give an upper bound on the impact
of vaccinating children using the ﬁnal attack rates in
different age groups, extrapolated from Zimmer et al.
[30]. We want to point out that, in principle, it is possible
that better surveillance data for the epidemic’s pro-
gression can produce sharper, real-time estimates of the
impact of vaccinating children. Such surveillance data
can come from serial serological data [31], or from age-
stratiﬁed data on ILI and respiratory specimen testing,
combined with a real-time serological study, or possibly
from syndromic data [32]. The practical aspects of
obtaining such data in real time remain uncertain [33].
An assumption we make in our approach is that, as
time progresses, depletion of susceptibles owing to natural
infections in high-risk groups is slower than the depletion
of susceptibles in the whole population (particularly
among children and the young adults); thus, the relative
risk for the unvaccinated subgroup of a high-risk group
increases with time. The role of young individuals
during the early stages of an epidemic and their sub-
sequent depletion is known [8], and evidence for the
decline of the relative share of the young individuals
a m o n gt h ei n f e c t e dc a nb es e e ni nt h eI L Id a t a[ 14].
More evidence for the assumption on the increasing rela-
tive risk of severe outcomes in the high-risk groups
is provided by Flu.Gov [3]. However, those considerations
need not imply that relative risks in each high-risk group
increase with time. Children and young adults represent a
small fraction of fatal cases, and adults in certain high-
risk groups might be more susceptible to infection than
other adults in the corresponding age groups, experien-
cing a larger initial depletion of susceptibles and
correspondingly lower relative risk of fatality in later
stages of an epidemic. To assess this issue, one can
measure the share of individuals with a particular under-
lying health condition for a certain recorded outcome, e.g.
hospitalization, in different age groups. Changes in their
relative share through time should give an indication
aboutthechangeintheirrelativeriskoffatalitycompared
with the early stages of the epidemic.
Yet another assumption in our approach is that the
impact of further vaccination and depletion of susceptible
individuals is stronger than the impact of seasonality or
genetic changes affecting the transmissibility of the virus.
For the 2009 H1N1pdm this assumption with regard to
seasonality was violated in southeastern USA owing to
little willingness in the population to get vaccinated
when vaccine was widely available. It is reasonable to
assume that for a more pathogenic strain this factor
would play a lesser role. At the same time, the decline
rate of the epidemic in the southeast was low and a winter-
time resurgence owing to seasonal forcing could be
predicted [34]. Moreover, under the approach of this
paper, such a low decline rate would justify prioritization
of risk groups whose relative risks for fatal outcomes are
higher than those existing in the published data.
Some regions of the USA, such as New England, had
high H1N1pdm vaccination rates and a decline in the
epidemic which was sustained through the winter.
We assess our criterion for New England and specify
the high-risk groups which should have been initially
prioritized for vaccination over school-aged children,
under certain assumptions on vaccine efﬁcacy against
mortality in those high-risk groups. We note that
there is a wide range of uncertainty in the available
data for the 2009 H1N1 pandemic with regard to the
estimates for the relative risk of mortality for individ-
uals with various underlying conditions, as well as for
the attack rates and the relative susceptibility and
infectivity in the different population groups. More
detailed epidemiological data would reduce the above
uncertainties, and correspondingly the uncertainty in
our conclusions for vaccine prioritization.
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